针对MKNK2的MIR-125b定向调节可以抑制多发性骨髓瘤的扩散和侵入
Binbin Tan1, Gaohui Yang1, Liangyan Su1
1Department of Hematology, The First Affiliated Hospital of Guangxi Medical University Nanning 530021, Guangxi, China.
American journal of translational research
|August 8, 2024
概括
微RNA-125b (miR-125b) 通过抑制MKNK2基因来抑制多发性骨髓瘤 (MM) 的进展. 这一发现揭示了miR-125b作为MM治疗的潜在治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因规则 基因规则
背景情况:
- 异常的微RNA (miRNA) 表达与瘤进展有关.
- 在多发性骨髓瘤 (MM) 病原发生过程中,miR-125b的特定作用尚不清楚.
研究的目的:
- 研究miR-125b在多发性骨髓瘤中的功能作用和潜在的分子机制.
- 确定miR-125b是否影响MM细胞行为,并确定其直接目标.
主要方法:
- 定量实时PCR测量MM组织中的miR-125b和MKNK2表达.
- 在体外测定包括殖民地形成,细胞计数Kit-8 (CCK-8) 和Transwell测定以评估扩散和入侵.
- 双 luciferase 记者和西部斑点测定验证MKNK2作为miR-125b的直接目标.
主要成果:
- 在MM组织中,miR-125b表达升高,与MKNK2水平相反相关.
- 证实MKNK2是MM细胞中miR-125b的直接下游标.
- 过度表达miR-125b显著抑制了MM细胞的增殖,殖民地形成和入侵.
- MKNK2调解了miR-125b对MM细胞恶性行为的抑制作用.
结论:
- 在多发性骨髓瘤中,miR-125b作为瘤抑制剂起作用.
- 通过miR-125b对MKNK2的调节是通过miR-125b影响MM细胞生长和入侵的关键机制.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K


